1.HPV Vaccine, Is It Really Harmful?.
Journal of Korean Medical Science 2014;29(6):749-750
2.Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.
Feng-Cai ZHU ; Chang-Gui LI ; Hong-Xing PAN ; Yi-Ju ZHANG ; Dan BI ; Hai-Wen TANG ; Sanjoy DATTA
Chinese Journal of Cancer 2011;30(8):559-564
Globally, about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection. A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples. The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions. This phase I trial (NCT00549900) assessed the safety, tolerability, and immunogenicity of the vaccine in Chinese. Thirty healthy Chinese females, aged 15 to 45 years with a median age of 29.5 years, received three doses of Cervarix in Months 0, 1, and 6. Safety was assessed via recording solicited local and systemic symptoms within 7 days and unsolicited symptoms within 30 days after each vaccination. Serious adverse events, new onset of chronic diseases, and other medically significant conditions were recorded throughout this trial. As an exploratory objective, HPV-16/18 antibody titers were determined by enzyme-linked immunosorbent assay in serum samples collected in Months 0 and 7. Pain at the injection site was the most frequently reported local symptom. Two subjects reported medically significant adverse events. Both cases were assessed as unrelated to vaccination by the investigator. In Month 7, 100% seroconversion was observed for both anti-HPV-16 and anti-HPV-18 with high geometric mean antibody titers. HPV-16/18 AS04-adjuvanted vaccine, evaluated for the first time in Chinese females, was generally well tolerated and immunogenic, as previously shown in global studies.
Adjuvants, Immunologic
;
Adolescent
;
Adult
;
Antibodies, Viral
;
blood
;
Asian Continental Ancestry Group
;
China
;
Female
;
Human papillomavirus 16
;
immunology
;
Human papillomavirus 18
;
immunology
;
Humans
;
Middle Aged
;
Papillomavirus Infections
;
immunology
;
prevention & control
;
virology
;
Papillomavirus Vaccines
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Uterine Cervical Neoplasms
;
immunology
;
prevention & control
;
virology
;
Young Adult
3.Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years.
Young Jae KIM ; Kyung Tai KIM ; Jae Hoon KIM ; Soon Do CHA ; Jae Weon KIM ; Duk Soo BAE ; Joo Hyun NAM ; Woong Shick AHN ; Ho Sun CHOI
Journal of Korean Medical Science 2010;25(8):1197-1204
The human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine has been demonstrated to be highly efficacious and immunogenic with a favorable safety profile. This study assessed the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Korean girls aged 10-14 yr. This multi-center, observer-blind trial randomly assigned 321 healthy girls to receive three doses (0, 1, 6-month schedule) of HPV-16/18 AS04-adjuvanted vaccine or hepatitis A vaccine. Immunogenicity against vaccine antigens was assessed one month post-Dose 3. Solicited and unsolicited adverse events (AEs) and serious AEs (SAEs) were recorded. In the according-to-protocol analysis, all initially seronegative subjects vaccinated with the HPV-16/18 AS04-adjuvanted vaccine had seroconverted at Month 7, with a peak geometric mean titer (GMT) that was 600-fold higher than the natural infection titer of 29.8 EU/mL for HPV-16 and a peak GMT that was 400-fold higher than the natural infection titer of 22.6 EU/mL for HPV-18. The vaccine was well tolerated with no increase in reactogenicity with subsequent doses and no reports of vaccine-related SAEs. In conclusion, the HPV-16/18 AS04-adjuvanted vaccine is shown to be highly immunogenic and generally well-tolerated in Korean girls aged 10-14 yr.
Adjuvants, Immunologic/administration & dosage
;
Adolescent
;
Aluminum Hydroxide/administration & dosage
;
Antibodies, Viral/analysis
;
Child
;
Female
;
Hepatitis A/immunology
;
Hepatitis A Vaccines/administration & dosage/adverse effects/immunology
;
Humans
;
Lipid A/administration & dosage/analogs & derivatives
;
Papillomavirus Infections/*prevention & control
;
Papillomavirus Vaccines/administration & dosage/adverse effects/*immunology
;
Republic of Korea
;
Seroepidemiologic Studies
;
Uterine Cervical Neoplasms/*prevention & control